Clinical Trials on Coagulation and Hemorrhagic Disorders in United States

Total 60837 results

The University of Texas Health Science Center,...

Completed

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

Hemophilia A

United States
Enzyre B.V.
Indiana Hemophilia & Thrombosis Center

Not yet recruiting

Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia A Monitoring

Hemophilia A

United States
Boston VA Research Institute, Inc.
University of Michigan; Emory University; Shire

Withdrawn

Improved Factor VIII Inhibitor Evaluation (IFIE)

Hemophilia A | Hemophilia

United States
Emory University

Completed

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Hemophilia A

United States
Victor J Marder, M.D.
Baxter Healthcare Corporation

Unknown

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia (PPTIH)

Hemophilia A

United States
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
BioMarin Pharmaceutical

Completed

A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A (SAAVY)

Hemophilia A

United States
Bayer

Completed

Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Hemophilia A

United States
Children's Hospital Los Angeles

Completed

Individualizing Hemophilia Prophylaxis Using Thromboelastography

Hemophilia A

United States
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Macedonia, The Former Yugoslav Republic of, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Israel, Russian Federation, Turkey, Lithuania, Poland, Japan, Latvia, Puerto...
BioMarin Pharmaceutical

Completed

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg (GENEr8-2)

Hemophilia A

United States
Wake Forest University Health Sciences

Active, not recruiting

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage (FITCH)

Stroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage Intraparenchymal

United States
Oregon Health and Science University

Completed

Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)

Hemophilia

United States
King's College Hospital NHS Trust
University Hospital Birmingham

Completed

An Observational Pilot Study of the Effects of Traumatic Haemorrhagic Shock and Resuscitation on the Microcirculation (MICROSHOCK)

Traumatic Haemorrhagic Shock

United Kingdom
ASC Therapeutics

Recruiting

ASC618 Gene Therapy in Hemophilia A Patients

Hemophilia A

United States
Novo Nordisk A/S

Terminated

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

United States
Weill Medical College of Cornell University

Withdrawn

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

Von Willebrand Disease

United States
The University of Texas Health Science Center,...
The ZLB Behring Foundation

Terminated

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

Von Willebrand Disease

United States
Montefiore Medical Center
Genentech, Inc.

Not yet recruiting

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Hemophilia A

United States
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
Bayer

Terminated

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (guardian™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
Wayne State University
Genentech, Inc.

Recruiting

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis (STEP)

Hemophilia A

United States
Boston Children's Hospital
Baxter Healthcare Corporation

Completed

Platelet Function in Patients With Hemophilia A

Hemophilia A

United States
Centers for Disease Control and Prevention

Completed

Treatment and Management of Women With Bleeding Disorders

Blood Coagulation Disorders | Blood Platelet Disorders | Menorrhagia | Hematologic Disease | Von Willebrand Disease

United States
Georgetown University

Completed

Biomarkers Serum Collection Methodology Pilot Study

Hemophilia A

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Australia, France, Thailand, Italy, Malaysia, Austria, Greece, Japan, Taiwan, Canada, Israel, Algeria, Argentina, Bulgaria, Germany, Romania
CAMC Health System

Withdrawn

The Natural History of Procalcitonin in Hemorrhagic Stroke

Intraventricular Hemorrhage | Intracerebral Hemorrhage

United States
Indiana Hemophilia &Thrombosis Center, Inc.
Genentech, Inc.

Recruiting

Hemlibra in Mild Hemophilia A

Factor VIII Deficiency, Congenital

United States
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Eradication Trial

Hemophilia A With Inhibitor

United States
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Completed

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (RESIST EXP)

Severe Hemophilia A

United States
Margaret Ragni

Withdrawn

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (INHIBIT)

Severe Hemophilia A

United States
Nationwide Children's Hospital
The Hospital for Sick Children

Completed

Exercise Versus DDAVP in Patients With Mild Hemophilia A

Hemophilia A

United States
Margaret Ragni
Wyeth is now a wholly owned subsidiary of Pfizer; University of North Carolina

Terminated

IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

United States
Craig Seaman

Terminated

Weight-based Dosing in Hemophilia A

Hemophilia

United States
Mary M. Gooley Hemophilia Center

Completed

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

Hemophilia | vonWillebrand Disease | Platelet Coagulation Disorders

United States
University College, London
Medical Research Council

Recruiting

Gene Therapy for Haemophilia A. (GO-8)

Hemophilia A

United States, United Kingdom
Nicklaus Children's Hospital f/k/a Miami Children...

Completed

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery (RiaSTAP)

Afibrinogenemia | Hypofibrinogenemia | Bleeding Disorders

United States
Eli Lilly and Company
Sigilon Therapeutics, Inc.

Terminated

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Hemophilia A

United Kingdom, United States
Children's Hospital Los Angeles
Takeda

Active, not recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Hemophilia A With Inhibitor

United States
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
Healthcare Innovation Technology Lab
Bayer

Unknown

Hemophilia Mobile App Usability Pilot

Hemophilia

United States
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Novo Nordisk A/S

Terminated

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding (CONTROL)

Trauma | Acquired Bleeding Disorder

Spain, Hong Kong, Germany, France, United Kingdom, Brazil, Italy, Hungary, Netherlands, United States, Switzerland, Czech Republic, Greece, South Africa
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
Bayer

Completed

Colorado Adult Joint Assessment Scale (CAJAS) Validation (CAJAS)

Hemophilia A

United States
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (Alfa-PROTECT)

Hemophilia A | Children | Prophylaxis of Bleeding | Treatment of Bleeding

Canada, United States, Brazil, Italy, Turkey, Argentina, Norway

Clinical Trials on Coagulation and Hemorrhagic Disorders in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations